Kodiak Sciences Inc (KOD) Stock Price & How to Invest

Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degeneration (wet AMD), and macular edema. Its programs are built on an antibody biopolymer conjugate (ABC) platform intended to extend how long a single injection lasts in the eye. The lead candidate, tarcocimab tedromer (branded Zenkuda), delivered positive Phase 3 GLOW2 data in diabetic retinopathy in early 2026, while additional Phase 3 studies (DAYBREAK in wet AMD with KSI-501, and PEAK and PINNACLE for KSI-101 in macular edema secondary to inflammation) are reading out into 2027.

The investment picture is that of a classic late-stage biotech: no product revenue, ongoing net losses funded by cash on hand, and a valuation driven almost entirely by clinical and regulatory expectations. Kodiak has a notable history, with an earlier wet AMD trial failure in 2021 that sharply cut the stock, so the current setup is often framed as a clinical redemption story. Whether the company reaches a first commercial approval, and how any launch competes against entrenched anti-VEGF drugs, will matter far more than any near-term income statement line.

As a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. Even positive data does not guarantee FDA approval, and a first commercial launch would face entrenched competitors including Regeneron's Eylea franchise and Roche's Vabysmo, plus lower-cost off-label and biosimilar options. The company burns cash (net loss of roughly $58 million in Q1 2026) and has stated runway only into 2027, so additional dilutive financing is a realistic possibility. Ophthalmology commercialization is capital-intensive, and durability claims must hold up in real-world use to justify premium positioning.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kodiak Sciences Inc's investor relations page or your broker.

• Revenue (TTM): ~$0 (no approved products)
• Net loss (Q1 2026): ~$58M
• R&D expense (Q1 2026): ~$49M
• Cash & equivalents (Mar 2026): ~$170M
• Shares outstanding: ~62M
• Market cap: ~$1.3B

Kodiak has no product revenue and posts steady net losses, so traditional earnings multiples do not apply and valuation reflects pipeline expectations. Cash of roughly $170 million against a quarterly burn near $58 million supports operations into 2027, meaning further financing could be needed. The market capitalization near $1.3 billion effectively prices in the probability-weighted value of its Phase 3 programs.

There are three common ways to get KOD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so KOD sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where KOD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

KOD is a binary, pre-revenue biotech story where the value hinges on late-stage trial data and a first approval, not on today's financials.

Whether KOD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KOD a buy?, and where the stock could go from here in the KOD stock forecast.

For income investors, whether KOD pays a dividend and how the payout looks is covered in does KOD pay a dividend?